Contents

Search

Yaz

Extended cycle oral contraceptive. Contains: ethinyl estradiol 20 g, drospirenone 3 mg Indications: 1) prevention of pregnancy 2) premenstrual dysphoric disorder (PMDD) Contraindications: (Cautions) 1) may be less effective in women > 150 lbs 2) patients at risk of hyperkalemia a) renal insufficiency b) hepatic insufficiency c) adrenal insufficiency 3) NOT a weight-loss agent Dosage: - 24 days of ethinyl estradiol 20 ug, 1 mg norethindrone plus 4 days of placebo Adverse effects: - drospirenone may increase serum K+ levels [3] - drospirenone may increase of venous thromboembolism [4] Drug interactions: - concurrent administration agents increasing serum K+ - ACE inhibitors - angiotensin II receptor antagonists - K+ sparing diuretics - K+ supplements - NSAIDs - salt substitutes

General

monophasic oral contraceptive

References

  1. Prescriber's Letter 13(4): 2006 Hormonal Contraception Detail-Document#: 220415 (subscription needed) http://www.prescribersletter.com
  2. Prescriber's Letter 13(11): 2006 Yaz for PMDD Detail-Document#: 221110 (subscription needed) http://www.prescribersletter.com
  3. Prescriber's Letter 16(10): 2009 Safety of Drospirenone-Containing Oral Contraceptives Detail-Document#: 251007 (subscription needed) http://www.prescribersletter.com
  4. FDA Safety Alert: Posted 05/31/2011 Birth Control Pills Containing Drospirenone: Possible Increased Risk of Blood Clots http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm257337.htm

Component-of

Beyaz

Components

drospirenone ethinyl estradiol